Somatic loss of the remaining allele occurs approximately in half of CHEK2-driven breast cancers and is accompanied by a border-line increase of chromosomal instability-Reference-Cited by-同舟云学术

Somatic loss of the remaining allele occurs approximately in half of CHEK2-driven breast cancers and is accompanied by a border-line increase of chromosomal instability

Published:2022-01-12 Issue:2 Volume:192 Page:283-291
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Iyevleva Aglaya G.^ORCID,Aleksakhina Svetlana N.,Sokolenko Anna P.,Baskina Sofia V.,Venina Aigul R.,Anisimova Elena I.,Bizin Ilya V.,Ivantsov Alexandr O.,Belysheva Yana V.,Chernyakova Alexandra P.,Togo Alexandr V.,Imyanitov Evgeny N.

Funder

Russian Science Foundation

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s10549-022-06517-3.pdf

Reference49 articles.

1. Sokolenko AP, Bogdanova N, Kluzniak W, Preobrazhenskaya EV, Kuligina ES, Iyevleva AG, Aleksakhina SN, Mitiushkina NV, Gorodnova TV, Bessonov AA, Togo AV, Lubiński J, Cybulski C, Jakubowska A, Dörk T, Imyanitov EN (2014) Double heterozygotes among breast cancer patients analyzed for BRCA1, CHEK2, ATM, NBN/NBS1, and BLM germ-line mutations. Breast Cancer Res Treat 145(2):553–562. https://doi.org/10.1007/s10549-014-2971-1

2. Schutte M, Seal S, Barfoot R, Meijers-Heijboer H, Wasielewski M, Evans DG, Eccles D, Meijers C, Lohman F, Klijn J, van den Ouweland A, Futreal PA, Nathanson KL, Weber BL, Easton DF, Stratton MR, Rahman N, Breast Cancer Linkage Consortium (2003) Variants in CHEK2 other than 1100delC do not make a major contribution to breast cancer susceptibility. Am J Hum Genet 72(4):1023–1028. https://doi.org/10.1086/373965

3. Weischer M, Bojesen SE, Ellervik C, Tybjaerg-Hansen A, Nordestgaard BG (2008) CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls. J Clin Oncol 26(4):542–548. https://doi.org/10.1200/JCO.2007.12.5922